Brief: FDA Approves Taletrectinib For ROS1-Positive Non-Small Cell Lung Cancer
11/06/2025 18:02
June 11 (Reuters) - FDA: FDA: APPROVES TALETRECTINIB FOR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER Further company coverage: NUVB.N
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth